Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
European Lung Foundation
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Scientists in the UK propose that adults and teenagers should be the main target groups for tuberculosis (TB) vaccination programmes in the future.
This came out of their study, published in the journal, Proceedings of the National Academy of Sciences, which involved using a mathematical model to estimate the effectiveness of a range of vaccination methods if they were to be used between 2024 and 2050 in low- and middle-income countries.
Their results suggest that vaccinating teenagers and adults in these countries would have the greatest impact and be the most cost-effective strategy to eliminate tuberculosis (TB) by 2050.
This differs from current widely-used methods, which involves giving the Bacille Calmette–Guérin (BCG) to children.
The authors note that there are limitations to their predictions, and state that they should be treated as estimates rather than precise forecasts.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79